These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 25393440)

  • 1. [Basic in vitro studies on VEGF inhibition with aflibercept: similarities and differences to other VEGF-binding therapeutic proteins].
    Lang GE; Lang GK; Deissler HL
    Klin Monbl Augenheilkd; 2015 Mar; 232(3):295-302. PubMed ID: 25393440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells.
    Deissler HL; Lang GK; Lang GE
    Exp Eye Res; 2014 May; 122():20-31. PubMed ID: 24631334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A.
    Yang J; Wang X; Fuh G; Yu L; Wakshull E; Khosraviani M; Day ES; Demeule B; Liu J; Shire SJ; Ferrara N; Yadav S
    Mol Pharm; 2014 Oct; 11(10):3421-30. PubMed ID: 25162961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The revolution in the treatment of retinal diseases: anti-VEGF treatment at the Assuta Eye Institute].
    Katz G; Zehavi C; Treister G
    Harefuah; 2015 Apr; 154(4):270-3, 278. PubMed ID: 26065226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic Biodistribution and Intravitreal Pharmacokinetic Properties of Bevacizumab, Ranibizumab, and Aflibercept in a Nonhuman Primate Model.
    Christoforidis JB; Briley K; Binzel K; Bhatia P; Wei L; Kumar K; Knopp MV
    Invest Ophthalmol Vis Sci; 2017 Nov; 58(13):5636-5645. PubMed ID: 29094168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of aflibercept (EYLEA
    Schicht M; Hesse K; Schröder H; Naschberger E; Lamprecht W; Garreis F; Paulsen FP; Bräuer L
    Ann Anat; 2017 May; 211():135-139. PubMed ID: 28279730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VEGF but not PlGF disturbs the barrier of retinal endothelial cells.
    Deissler HL; Deissler H; Lang GK; Lang GE
    Exp Eye Res; 2013 Oct; 115():162-71. PubMed ID: 23891860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeys.
    Tschulakow A; Christner S; Julien S; Ludinsky M; van der Giet M; Schraermeyer U
    PLoS One; 2014; 9(11):e113701. PubMed ID: 25415380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transport and fate of aflibercept in VEGF-A
    Deissler HL; Sommer K; Lang GK; Lang GE
    Exp Eye Res; 2020 Sep; 198():108156. PubMed ID: 32712182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraocular pressure in patients with neovascular age-related macular degeneration switched to aflibercept injection after previous anti-vascular endothelial growth factor treatments.
    Rusu IM; Deobhakta A; Yoon D; Lee M; Slakter JS; Klancnik JM; Thompson D; Freund KB
    Retina; 2014 Nov; 34(11):2161-6. PubMed ID: 25072648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).
    Stewart MW; Rosenfeld PJ; Penha FM; Wang F; Yehoshua Z; Bueno-Lopez E; Lopez PF
    Retina; 2012 Mar; 32(3):434-57. PubMed ID: 22374154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of bevacizumab, ranibizumab and aflibercept on cell viability, phagocytosis and mitochondrial bioenergetics of retinal pigment epithelial cell.
    Sheu SJ; Chao YM; Liu NC; Chan JY
    Acta Ophthalmol; 2015 Dec; 93(8):e631-43. PubMed ID: 25975662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fusion Proteins: Aflibercept (VEGF Trap-Eye).
    Sarwar S; Bakbak B; Sadiq MA; Sepah YJ; Shah SM; Ibrahim M; Do DV; Nguyen QD
    Dev Ophthalmol; 2016; 55():282-94. PubMed ID: 26501481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
    Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
    Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes.
    MacDonald DA; Martin J; Muthusamy KK; Luo JK; Pyles E; Rafique A; Huang T; Potocky T; Liu Y; Cao J; Bono F; Delesque N; Savi P; Francis J; Amirkhosravi A; Meyer T; Romano C; Glinka M; Yancopoulos GD; Stahl N; Wiegand SJ; Papadopoulos N
    Angiogenesis; 2016 Jul; 19(3):389-406. PubMed ID: 27234973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fate of the Fc fusion protein aflibercept in retinal endothelial cells: competition of recycling and degradation.
    Deissler HL; Lang GK; Lang GE
    Graefes Arch Clin Exp Ophthalmol; 2019 Jan; 257(1):83-94. PubMed ID: 30367290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aflibercept Traps Galectin-1, an Angiogenic Factor Associated with Diabetic Retinopathy.
    Kanda A; Noda K; Saito W; Ishida S
    Sci Rep; 2015 Dec; 5():17946. PubMed ID: 26648523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PERMEABILITY AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR EFFECTS OF BEVACIZUMAB, RANIBIZUMAB, AND AFLIBERCEPT IN POLARIZED RETINAL PIGMENT EPITHELIAL LAYER IN VITRO.
    Yoshihara N; Terasaki H; Shirasawa M; Kawano H; Sonoda S; Yamaguchi M; Hashiguchi T; Hisatomi T; Ishibashi T; Sakamoto T
    Retina; 2017 Jan; 37(1):179-190. PubMed ID: 28005721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ranibizumab and Aflibercept: Intraocular Pharmacokinetics and Their Effects on Aqueous VEGF Level in Vitrectomized and Nonvitrectomized Macaque Eyes.
    Niwa Y; Kakinoki M; Sawada T; Wang X; Ohji M
    Invest Ophthalmol Vis Sci; 2015 Oct; 56(11):6501-5. PubMed ID: 26447985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo antivascular endothelial growth factor treatment induces corneal endothelium apoptosis in rabbits through changes in p75NTR-proNGF pathway.
    Gharbiya M; Bruscolini A; Sacchetti M; Rosso P; Carito V; Segatto M; Fico E; Tirassa P; Lambiase A
    J Cell Physiol; 2018 Nov; 233(11):8874-8883. PubMed ID: 29856479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.